正大天晴PD-L1单抗获批一线治疗和巩固治疗NSCLC

动脉网
Feb 14

2月14日国家药监局官网显示,正大天晴PD-L1单抗贝莫苏拜单抗获批新适应症,可联合盐酸安罗替尼胶囊一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)患者,或作为III期NSCLC患者的巩固治疗。III期CAMPASS研究显示,贝莫苏拜单抗联合安罗替尼组PD-L1阳性NSCLC患者中位无进展生存期(PFS)达11个月,较帕博利珠单抗组提升3.9个月,疾病进展/死亡风险降低30%(HR=0.70);...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10